ASP8374

DRUG3 trials

Sponsors

Astellas Pharma Global Development, Inc., Astellas Pharma Inc, Dana-Farber Cancer Institute

Conditions

Advanced Solid TumorsGlioblastomaRecurrent Glioblastoma

Phase 1

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

CompletedNCT03260322

Astellas Pharma Global Development, Inc.Advanced Solid Tumors

Start: 2017-09-08End: 2022-05-10Updated: 2025-04-24

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

CompletedNCT03945253

Astellas Pharma IncAdvanced Solid Tumors

Start: 2019-08-05End: 2020-06-12Updated: 2024-11-13

ASP8374 + Cemiplimab in Recurrent Glioma

CompletedNCT04826393

Dana-Farber Cancer InstituteGlioblastoma, Recurrent Glioblastoma

Start: 2022-03-09End: 2024-01-01Updated: 2025-10-22

Related Papers

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations